Fecal Calprotectin and Phenotype Severity in Patients with Cystic Fibrosis: A Systematic Review and Meta-Analysis

다국어 초록 (Multilingual Abstract)

Inflammation plays an important role in the outcome of patients with cystic fibrosis (CF). It may develop due to cystic fibrosis transmembrane conductance regulator protein dysfunction, pancreatic insufficiency, or prolonged pulmonary infection. Fecal calprotectin (FC) has been used as a noninvasive method to detect inflammation. Therefore, the aim of the current meta-analysis was to investigate the relationship between FC and phenotype severity in patients with CF. In this study, searches were conducted in PubMed, Science Direct, Scopus, and Embase databases up to August 2021 using terms such as “cystic fibrosis,” “intestine,” “calprotectin,” and “inflammation.” Only articles published in English and human studies were selected. The primary outcome was the level of FC in patients with CF. The secondary outcome was the relationship between FC and clinical severity. Statistical analysis was performed using Comprehensive Meta-Analysis software. Of the initial 303 references, only six articles met the inclusion criteria. The mean (95% confidence interval [CI]) level of FC was 256.5 mg/dL (114.1-398.9). FC levels were significantly associated with pancreatic insufficiency (mean, 243.02; 95% CI, 74.3 to 411.6; p=0.005; I2=0), pulmonary function (r=–0.39; 95% CI, –0.58 to –0.15; p=0.002; I2=60%), body mass index (r=–0.514; 95% CI, 0.26 to 0.69; p<0.001; I2=0%), and Pseudomonas colonization (mean, 174.77; 95% CI, 12.5 to 337.02; p=0.035; I2=71%). While FC is a reliable noninvasive marker for detecting gastrointestinal inflammation, it is also correlated with the severity of the disease in patients with CF.

참고문헌 (Reference)

1 Héry-Arnaud G, "The lung and gut microbiome : what has to be taken into consideration for cystic fibrosis?" 18 : 13-21, 2019

2 Melsen WG, "The effects of clinical and statistical heterogeneity on the predictive values of results from meta-analyses" 20 : 123-129, 2014

3 Więcek S, "The concentration of calprotectin in the stools of children with diagnosed cystic fibrosis" 12 : 38-43, 2017

4 Parisi GF, "Severe disease in Cystic Fibrosis and fecal calprotectin levels" 222 : 582-586, 2017

5 Sterne JA, "ROBINS-I : a tool for assessing risk of bias in non-randomised studies of interventions" 355 : i4919-, 2016

6 Belcher CN, "Protein processing and inflammatory signaling in cystic fibrosis : challenges and therapeutic strategies" 10 : 82-94, 2010

7 Moher D, "Preferred reporting items for systematic reviews and meta-analyses : the PRISMA statement" 8 : 336-341, 2010

8 Taylor-Cousar JL, "Potential of anti-inflammatory treatment for cystic fibrosis lung disease" 3 : 61-74, 2010

9 Briars G, "Intestinal inflammation in cystic fibrosis" 84 : 374-375, 2001

10 Dhaliwal J, "Intestinal inflammation and impact on growth in children with cystic fibrosis" 60 : 521-526, 2015

11 Cantin AM, "Inflammation in cystic fibrosis lung disease : pathogenesis and therapy" 14 : 419-430, 2015

12 Roesch EA, "Inflammation in cystic fibrosis : an update" 53 (53): S30-50, 2018

13 Stallings VA, "Improved residual fat malabsorption and growth in children with cystic fibrosis treated with a novel oral structured lipid supplement : a randomized controlled trial" 15 : e0232685-, 2020

14 Marsland BJ, "Host-microorganism interactions in lung diseases" 14 : 827-835, 2014

15 Coffey MJ, "Gut microbiota in children with cystic fibrosis : a taxonomic and functional dysbiosis" 9 : 18593-, 2019

16 Sabharwal S, "Gastrointestinal manifestations of cystic fibrosis" 12 : 43-47, 2016

17 Ellemunter H, "Fecal calprotectin in cystic fibrosis and its relation to disease parameters : a longitudinal analysis for 12 years" 65 : 438-442, 2017

18 Werlin SL, "Evidence of intestinal inflammation in patients with cystic fibrosis" 51 : 304-308, 2010

19 Adriaanse MP, "Evidence for a cystic fibrosis enteropathy" 10 : e0138062-, 2015

20 Werlin S, "Enteropathy – a new finding in cystic fibrosis" 7 (7): S79-, 2008

21 Anderson JL, "Effect of probiotics on respiratory, gastrointestinal and nutritional outcomes in patients with cystic fibrosis : a systematic review" 16 : 186-197, 2017

22 Bjerke K, "Distribution of macrophages and granulocytes expressing L1 protein(calprotectin)in human Peyer’s patches compared with normal ileal lamina propria and mesenteric lymph nodes" 34 : 1357-1363, 1993

23 Bruzzese E, "Disrupted intestinal microbiota and intestinal inflammation in children with cystic fibrosis and its restoration with Lactobacillus GG : a randomised clinical trial" 9 : e87796-, 2014

24 Schnapp Z, "Decreased fecal calprotectin levels in cystic fibrosis patients after antibiotic treatment for respiratory exacerbation" 68 : 282-284, 2019

25 Fraser-Pitt D, "Cystic fibrosis-a multiorgan protein misfolding disease" 1 : FSO57-, 2015

26 Lubamba B, "Cystic fibrosis : insight into CFTR pathophysiology and pharmacotherapy" 45 : 1132-1144, 2012

27 Stang A, "Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses" 25 : 603-605, 2010

28 Mack DR, "Correlation of intestinal lactulose permeability with exocrine pancreatic dysfunction" 120 : 696-701, 1992

29 Rumman N, "Calprotectin in cystic fibrosis" 14 : 133-, 2014

30 Dorsey J, "Bacterial overgrowth, dysbiosis, inflammation, and dysmotility in the Cystic Fibrosis intestine" 16 (16): S14-23, 2017

31 Norkina O, "Bacterial overgrowth in the cystic fibrosis transmembrane conductance regulator null mouse small intestine" 72 : 6040-6049, 2004

32 Hoen AG, "Associations between gut microbial colonization in early life and respiratory outcomes in cystic fibrosis" 167 : 138-147, 2015

33 de Freitas MB, "Altered intestinal microbiota composition, antibiotic therapy and intestinal inflammation in children and adolescents with cystic fibrosis" 13 : e0198457-, 2018

34 Garg M, "Age-related levels of fecal M2-pyruvate kinase in children with cystic fibrosis and healthy children 0 to 10years old" 17 : 109-113, 2018

35 Garg M, "Age-dependent variation of fecal calprotectin in cystic fibrosis and healthy children" 16 : 631-636, 2017